Key Points
- Insider sale: Director Neil Gregory Almstead sold 3,989 PTC shares on March 5 at $63.38 for about $252,823, reducing his direct stake by 59.31% to 2,737 shares (≈$173,471).
- Ongoing sell-off: Almstead has disposed of additional tranches in January and February, totaling over 10,000 shares sold year-to-date across multiple transactions.
- Company results and outlook: PTC missed expectations with Q4 EPS of -$1.67 vs. -$0.21 and revenue of $164.7M vs. $281.5M (revenue down 22.7% YoY); analysts hold a consensus "Moderate Buy" with an average target near $82.79.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) insider Neil Gregory Almstead sold 3,989 shares of PTC Therapeutics stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $63.38, for a total value of $252,822.82. Following the transaction, the insider directly owned 2,737 shares in the company, valued at approximately $173,471.06. The trade was a 59.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Neil Gregory Almstead also recently made the following trade(s):
- On Wednesday, February 18th, Neil Gregory Almstead sold 65 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.36, for a total transaction of $4,508.40.
- On Wednesday, February 18th, Neil Gregory Almstead sold 3,056 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.36, for a total transaction of $211,964.16.
- On Thursday, January 8th, Neil Gregory Almstead sold 59 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total transaction of $4,510.55.
- On Thursday, January 8th, Neil Gregory Almstead sold 881 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total transaction of $67,352.45.
- On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $4,028.96.
- On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $79,494.48.
- On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $4,155.30.
- On Tuesday, January 6th, Neil Gregory Almstead sold 1,279 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $98,419.05.
PTC Therapeutics Stock Performance
NASDAQ PTCT opened at $68.40 on Tuesday. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The business's fifty day moving average is $72.59 and its two-hundred day moving average is $69.59. The stock has a market capitalization of $5.66 billion, a P/E ratio of 8.84 and a beta of 0.51.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The business's revenue was down 22.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.85) earnings per share. On average, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.
Analyst Ratings Changes
PTCT has been the subject of a number of recent analyst reports. Wall Street Zen lowered PTC Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. Morgan Stanley upped their price objective on shares of PTC Therapeutics from $90.00 to $92.00 and gave the company an "overweight" rating in a research note on Monday, February 23rd. TD Cowen reiterated a "hold" rating on shares of PTC Therapeutics in a report on Thursday, January 29th. Barclays reissued an "overweight" rating and issued a $120.00 target price on shares of PTC Therapeutics in a research report on Monday, February 23rd. Finally, Wells Fargo & Company cut their price target on shares of PTC Therapeutics from $93.00 to $86.00 and set an "overweight" rating on the stock in a report on Friday, February 20th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $82.79.
Get Our Latest Analysis on PTC Therapeutics
Institutional Investors Weigh In On PTC Therapeutics
Hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its position in PTC Therapeutics by 3.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company's stock worth $388,000 after acquiring an additional 231 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 236 shares during the period. Allworth Financial LP increased its holdings in shares of PTC Therapeutics by 63.8% in the 4th quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company's stock valued at $48,000 after purchasing an additional 247 shares during the period. Optiver Holding B.V. lifted its position in shares of PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 249 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC lifted its position in shares of PTC Therapeutics by 5.6% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 4,963 shares of the biopharmaceutical company's stock worth $377,000 after purchasing an additional 265 shares in the last quarter.
PTC Therapeutics Company Profile
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
